Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 02, 2022

SELL
$1.23 - $1.9 $1,752 - $2,707
-1,425 Closed
0 $0
Q4 2021

Feb 02, 2022

SELL
$1.64 - $2.83 $1,408 - $2,430
-859 Reduced 37.61%
1,425 $2,000
Q3 2021

Nov 16, 2021

BUY
$2.7 - $3.59 $6,166 - $8,199
2,284 New
2,284 $7,000

Others Institutions Holding MBRX

About Moleculin Biotech, Inc.


  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $48.6M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track Migdal Insurance & Financial Holdings Ltd. Portfolio

Follow Migdal Insurance & Financial Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Migdal Insurance & Financial Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Migdal Insurance & Financial Holdings Ltd. with notifications on news.